drugset / Trial / NCT05018767

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty

NCT05018767

NaSingle-groupOpen-labelTreatment

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Aging Frailty

Timeline

Start
2022-01-22
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloRx Cell therapy 1e+08 cells Intravenous

Indications

No indication recorded.